Erratum: Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance(Nature Genetics (2016) DOI: 10.1038/ng.3714);Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance

Nature Genetics

Volumn 49, Issue 1, 2017, Pages 17-26

  Lotta, Luca A ^a   Gulati, Pawan ^a   Day, Felix R ^a   Payne, Felicity ^b   Ongen, Halit ^c   Van De Bunt, Martijn ^d,e   Gaulton, Kyle J ^f   Eicher, John D ^g   Sharp, Stephen J ^a   Luan, Jian'an ^a   De Lucia Rolfe, Emanuella ^a   Stewart, Isobel D ^a   Wheeler, Eleanor ^b   Willems, Sara M ^a   Adams, Claire ^a   Yaghootkar, Hanieh ^h   Forouhi, Nita G ^a   Kerrison, Nicola D ^a   Sims, Matt ^a   Lucarelli, Debora M E ^a   Deloukas, Panos ^a   McCarthy, Mark I ^d,e   Arriola, Larraitz ^i,j,k   Balkau, Beverley ^l,m   Barricarte, Aurelio ^k,n,o   Boeing, Heiner ^p   Franks, Paul W ^q,r   Gonzalez, Carlos ^s   Grioni, Sara ^t   Kaaks, Rudolf ^u   Key, Timothy J ^d   Navarro, Carmen ^k,v,w   Nilsson, Peter M ^q   Overvad, Kim ^x,y   Palli, Domenico ^z   Panico, Salvatore ^aa   Quirós, J Ramón ^ab   Rolandsson, Olov ^r   Sacerdote, Carlotta ^ac,ad   Salamanca Fernández, Elena ^k,ae,af   Slimani, Nadia ^ag   Tjonneland, Anne ^ah   Tumino, Rosario ^ai   Spijkerman, Annemieke M W ^aj   Van Der A, Daphne L ^aj   Van Der Schouw, Yvonne T ^ak   Riboli, Elio ^al   Semple, Robert K ^a   Stears, Anna ^am   George, Stella ^an   Walker, Mark ^ao   Gurnell, Ellie ^am   Maguire, Deirdre ^ap   Mukhtar, Rasha ^aq   Nag, Sath ^aq   Adler, Amanda ^am   Soeters, Maarten R ^ar   Laji, Ken ^as   Watt, Alistair ^at   Aylwin, Simon ^au   Johnson, Andrew ^av   Rayman, Gerry ^aw   Hanna, Fahmy ^ax   Ellard, Sian ^ay   Ross, Richard ^az   Blaslov, Kristina ^ba   Duvnjak, Lea Smirčić ^ba   Khaw, Kay Tee ^a   Johnson, Andrew D ^g   Frayling, Timothy ^h   Perry, John R B ^a   Dermitzakis, Emmanouil ^c   Barroso, Inês ^a,b   Wareham, Nicholas J ^a   Savage, David B ^a   Langenberg, Claudia ^a   O'Rahilly, Stephen ^a   Scott, Robert A ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

ⁱ Basque Government   (Spain)

^j BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^k CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^l CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^m UNIVERSITÉ PARIS SACLAY   (France)

ⁿ INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^o Recinto de Complejo Hospitalario de Navarra   (Spain)

^p GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^q LUND UNIVERSITY   (Sweden)

^r UMEÅ UNIVERSITY   (Sweden)

^s CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^t Epidemiology Unit   (Italy)

^u GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^v DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^w UNIVERSITY OF MURCIA   (Spain)

^x AARHUS UNIVERSITY   (Denmark)

^y AALBORG UNIVERSITY HOSPITAL   (Denmark)

^z CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^aa UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^ab PUBLIC HEALTH DIRECTORATE   (Spain)

^ac UNIVERSITY OF TURIN   (Italy)

^ad Human Genetics Foundation (HuGeF)   (Italy)

^ae ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^af Instituto De Investigación Biosanitaria de Granada Ibs GRANADA   (Spain)

^ag INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^ah DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^ai Servizio di Epidemiologia   (Italy)

^aj NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ak UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^al IMPERIAL COLLEGE LONDON   (United Kingdom)

^am ADDENBROOKE S HOSPITAL   (United Kingdom)

^an LISTER HOSPITAL   (United Kingdom)

^ao NEWCASTLE UNIVERSITY   (United Kingdom)

^ap HARROGATE DISTRICT HOSPITAL   (United Kingdom)

^aq JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^ar ACADEMIC MEDICAL CENTER   (Netherlands)

^as Department of Maxillofacial Surgery   (United Kingdom)

^at NORTH DEVON DISTRICT HOSPITAL   (United Kingdom)

^au KING S COLLEGE HOSPITAL   (United Kingdom)

^av SOUTHMEAD HOSPITAL   (United Kingdom)

^aw IPSWICH HOSPITAL   (United Kingdom)

^ax UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^ay ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^az UNIVERSITY OF SHEFFIELD   (United Kingdom)

^ba University of Zagreb   (Croatia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN INSULIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADIPOGENESIS; ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; FAMILIAL PARTIAL LIPODYSTROPHY; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC ASSOCIATION; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; GENOTYPE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIPID STORAGE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOSE TISSUE; ANALYSIS; ANIMAL; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; GENETICS; GLUCOSE BLOOD LEVEL; METABOLIC DISORDER; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC DISEASES; MICE; OBESITY; PHENOTYPE;

EID: 84995459787     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng0217-317c     Document Type: Erratum

References (100)

1. Samuel, V.T. & Shulman, G.I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126, 12-22 (2016).
2. Ginsberg, H.N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106, 453-458 (2000).
3. Shulman, G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 371, 1131-1141 (2014).
4. Lillioja, S. & Bogardus, C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab. Rev. 4, 517-540 (1988).
5. Perry, R.J., Samuel, V.T., Petersen, K.F. & Shulman, G.I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84-91 (2014).
6. Arner, P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14, 137-145 (2003).
7. Friedman, J.M. Obesity in the new millennium. Nature 404, 632-634 (2000).
8. Guilherme, A., Virbasius, J.V., Puri, V. & Czech, M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9, 367-377 (2008).
9. Friedman, J.M. A war on obesity, not the obese. Science 299, 856-858 (2003).
10. Hardy, O.T., Czech, M.P. & Corvera, S. What causes the insulin resistance underlying obesity? Curr. Opin. Endocrinol. Diabetes Obes. 19, 81-87 (2012).
11. Stefan, N., Häring, H.U., Hu, F.B. & Schulze, M.B. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 1, 152-162 (2013).
12. Robbins, A.L. & Savage, D.B. The genetics of lipid storage and human lipodystrophies. Trends Mol. Med. 21, 433-438 (2015).
13. Semple, R.K., Savage, D.B., Cochran, E.K., Gorden, P. & O'Rahilly, S. Genetic syndromes of severe insulin resistance. Endocr. Rev. 32, 498-514 (2011).
14. Samuel, V.T., Petersen, K.F. & Shulman, G.I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267-2277 (2010).
15. Danforth, E. Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat. Genet. 26, 13 (2000).
16. Unger, R.H. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol. Metab. 14, 398-403 (2003).
17. Virtue, S. & Vidal-Puig, A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome - an allostatic perspective. Biochim. Biophys. Acta 1801, 338-349 (2010).
18. Shulman, G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171-176 (2000).
19. Karpe, F. & Pinnick, K.E. Biology of upper-body and lower-body adipose tissue - link to whole-body phenotypes. Nat. Rev. Endocrinol. 11, 90-100 (2015).
20. Robbins, D.C. et al. The effect of diet on thermogenesis in acquired lipodystrophy. Metabolism 28, 908-916 (1979).
21. Shimomura, I., Hammer, R.E., Ikemoto, S., Brown, M.S. & Goldstein, J.L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401, 73-76 (1999).
22. Oral, E.A. et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570-578 (2002).
23. Gavrilova, O. et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105, 271-278 (2000).
24. Kim, J.Y. et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117, 2621-2637 (2007).
25. Gray, S.L. et al. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor γ function (P465L PPARγ) in mice. Diabetes 55, 2669-2677 (2006).
26. Medina-Gomez, G. et al. PPARγ2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3, e64 (2007).
27. Knowles, J.W. et al. Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. J. Clin. Invest. 126, 403 (2016).
28. Scott, R.A. et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat. Genet. 44, 991-1005 (2012).
29. Manning, A.K. et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat. Genet. 44, 659-669 (2012).
30. Salazar, M.R. et al. Comparison of the abilities of the plasma triglyceride/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance. Diab. Vasc. Dis. Res. 10, 346-352 (2013).
31. Scott, R.A. et al. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. Diabetes 63, 4378-4387 (2014).
32. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274-1283 (2013).
33. Prokopenko, I. et al. A central role for GRB10 in regulation of islet function in man. PLoS Genet. 10, e1004235 (2014).
34. Morris, A.P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44, 981-990 (2012).
35. Nikpay, M. et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat. Genet. 47, 1121-1130 (2015).
36. Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518, 187-196 (2015).
37. Kozaki, K. et al. Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation. J. Lipid Res. 34, 1765-1772 (1993).
38. Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N. Engl. J. Med. 374, 1134-1144 (2016).
39. Mailly, F. et al. A common variant in the gene for lipoprotein lipase (Asp9→Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 15, 468-478 (1995).
40. Avila, M. et al. Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: towards recommendation for molecular testing and management. Clin. Genet. http://dx.doi.org/10.1111/cge.12688 (2015).
41. Thauvin-Robinet, C. et al. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am. J. Hum. Genet. 93, 141-149 (2013).
42. Chudasama, K.K. et al. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am. J. Hum. Genet. 93, 150-157 (2013).
43. Dyment, D.A. et al. Mutations in PIK3R1 cause SHORT syndrome. Am. J. Hum. Genet. 93, 158-166 (2013).
44. Pers, T.H. et al. Biological interpretation of genome-wide association studies using predicted gene functions. Nat. Commun. 6, 5890 (2015).
45. Lane, J.M., Doyle, J.R., Fortin, J.P., Kopin, A.S. & Ordovás, J.M. Development of an OP9 derived cell line as a robust model to rapidly study adipocyte differentiation. PLoS One 9, e112123 (2014).
46. Yaghootkar, H. et al. Genetic evidence for a normal-weight "metabolically obese" phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 63, 4369-4377 (2014).
47. Lu, Y. et al. New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk. Nat. Commun. 7, 10495 (2016).
48. Kilpeläinen, T.O. et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat. Genet. 43, 753-760 (2011).
49. Yaghootkar, H. et al. Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension and heart disease. Diabetes 65, 2448-2460 (2016).
50. Biggs, M.L. et al. Association between adiposity in midlife and older age and risk of diabetes in older adults. J. Am. Med. Assoc. 303, 2504-2512 (2010).
51. Pischon, T. et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 359, 2105-2120 (2008).
52. Vague, J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am. J. Clin. Nutr. 4, 20-34 (1956).
53. Smith, U. Abdominal obesity: a marker of ectopic fat accumulation. J. Clin. Invest. 125, 1790-1792 (2015).
54. Després, J.P. & Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 444, 881-887 (2006).
55. Dahlman, I. et al. Numerous genes in loci associated with body fat distribution are linked to adipose function. Diabetes 65, 433-437 (2016).
56. Rydén, M., Andersson, D.P., Bergström, I.B. & Arner, P. Adipose tissue and metabolic alterations: regional differences in fat cell size and number matter, but differently: a cross-sectional study. J. Clin. Endocrinol. Metab. 99, E1870-E1876 (2014).
57. Pinnick, K.E. et al. Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 63, 3785-3797 (2014).
58. Baughman, B.M., Pattenden, S.G., Norris, J.L., James, L.I. & Frye, S.V. The L3MBTL3 methyl-lysine reader domain functions as a dimer. ACS Chem. Biol. 11, 722-728 (2016).
59. Randall, J.C. et al. Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet. 9, e1003500 (2013).
60. Paternoster, L. et al. Adult height variants affect birth length and growth rate in children. Hum. Mol. Genet. 20, 4069-4075 (2011).
61. Wood, A.R. et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat. Genet. 46, 1173-1186 (2014).
62. Gupta, G.D. et al. A dynamic protein interaction landscape of the human centrosome-cilium interface. Cell 163, 1484-1499 (2015).
63. Singaraja, R.R. et al. Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. J. Lipid Res. 55, 1693-1701 (2014).
64. Chasman, D.I. et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 5, e1000730 (2009).
65. DeFronzo, R.A. et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364, 1104-1115 (2011).
66. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096-1105 (2006).
67. Lincoff, A.M., Wolski, K., Nicholls, S.J. & Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J. Am. Med. Assoc. 298, 1180-1188 (2007).
68. Kernan, W.N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 374, 1321-1331 (2016).
69. Nissen, S.E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
70. Food and Drug Administration. Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes (Food and Drug Administration, 2008).
71. Swerdlow, D.I. et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385, 351-361 (2015).
72. Dewey, F.E. et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N. Engl. J. Med. 374, 1123-1133 (2016).
73. Do, R. et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518, 102-106 (2015).
74. Jørgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G. & Tybjærg-Hansen, A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371, 32-41 (2014).
75. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371, 22-31 (2014).
76. Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 371, 2072-2082 (2014).
77. Moltke, I. et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature 512, 190-193 (2014).
78. Day, N. et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br. J. Cancer 80 (Suppl. 1), 95-103 (1999).
79. Riboli, E. et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 5, 1113-1124 (2002).
80. InterAct Consortium. Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia 54, 2272-2282 (2011).
81. Collins, R. What makes UK Biobank special? Lancet 379, 1173-1174 (2012).
82. Lyssenko, V. et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 117, 2155-2163 (2007).
83. Aschard, H., Vilhjálmsson, B.J., Joshi, A.D., Price, A.L. & Kraft, P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. Am. J. Hum. Genet. 96, 329-339 (2015).
84. Day, F.R., Loh, P.R., Scott, R.A., Ong, K.K. & Perry, J.R. A robust example of collider bias in a genetic association study. Am. J. Hum. Genet. 98, 392-393 (2016).
85. Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol. 37, 658-665 (2013).
86. Lawrence, R.D. Types of human diabetes. BMJ 1, 373-375 (1951).
87. Herbst, K.L. et al. Köbberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 26, 1819-1824 (2003).
88. Payne, F. et al. Hypomorphism in human NSMCE2 linked to primordial dwarfism and insulin resistance. J. Clin. Invest. 124, 4028-4038 (2014).
89. UK10K Consortium. The UK10K project identifies rare variants in health and disease. Nature 526, 82-90 (2015).
90. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
91. Delaneau, O., Marchini, J. & Zagury, J.F. A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179-181 (2011).
92. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906-913 (2007).
93. Pruim, R.J. et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336-2337 (2010).
94. Ward, L.D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2012).
95. Johnson, A.D. et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24, 2938-2939 (2008).
96. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001-D1006 (2014).
97. Zhang, X. et al. Synthesis of 53 tissue and cell line expression QTL datasets reveals master eQTLs. BMC Genomics 15, 532 (2014).
98. Buil, A. et al. Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins. Nat. Genet. 47, 88-91 (2015).
99. GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648-660 (2015).
100. Nica, A.C. et al. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. PLoS Genet. 6, e1000895 (2010).